ID
43834
Beschrijving
XELODA and Lapatinib Advanced or Metastatic Breast Cancer Study ID: 100151 Clinical Study ID: EGF100151 Study Title: A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer Clinicaltrials.gov Identifier: NCT00078572 https://clinicaltrials.gov/ct2/show/NCT00078572 Procedure: Demography Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Breast Cancer; Neoplasms, Breast
Link
https://clinicaltrials.gov/ct2/show/NCT00078572
Trefwoorden
Versies (2)
- 18-05-17 18-05-17 -
- 20-09-21 20-09-21 -
Geüploaded op
20 september 2021
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
XELODA and Lapatinib Advanced or Metastatic Breast Cancer Demography NCT00078572
XELODA and Lapatinib Advanced or Metastatic Breast Cancer Demography NCT00078572
Beschrijving
Demography for Females
Alias
- UMLS CUI-1
- C0011298
- UMLS CUI-2
- C0086287
Beschrijving
Childbearing potential
Datatype
text
Alias
- UMLS CUI [1]
- C3831118
Beschrijving
contraception
Datatype
integer
Alias
- UMLS CUI [1,1]
- C0700589
- UMLS CUI [1,2]
- C0420837
Beschrijving
Contraception
Datatype
text
Alias
- UMLS CUI [1,1]
- C0700589
- UMLS CUI [1,2]
- C0420837
Beschrijving
Pregnancy test result
Datatype
text
Alias
- UMLS CUI [1]
- C0032976
Similar models
XELODA and Lapatinib Advanced or Metastatic Breast Cancer Demography NCT00078572
C0086287 (UMLS CUI-2)
C0420837 (UMLS CUI [1,2])
C0420837 (UMLS CUI [1,2])